Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
CONCORD, Mass., Oct. 4, 2022 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced a continuation of their collaboration with Celsius Therapeutics for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointment of Sarah Grant, M.D., as chief medical officer. In this role, Dr. Grant will lead the company’s clinical strategy and development of its pipeline of therapies for autoimmune disease and cancer, including its potential first-in-class TREM1 antibody program for inflammatory bowel disease.
The temperature is rising at Celsius Therapeutics as the precision-medicine-focused biotech picks a lead candidate and reels in $83 million in funding.
Servier, a global pharmaceutical Group, and Celsius Therapeutics, a company focused on bringing precision medicine to patients with cancer and autoimmunity, announced a strategic collaboration focused on the identification and validation of novel colorectal cancer (CRC) drug targets.
A well-known international pharmaceutical company and a relatively new US precision therapeutics startup are joining forces to identify and validate novel colorectal cancer drug targets.